Sensus Healthcare, a manufacturer and marketer of medical devices that incorporate superficial radiation therapy (SRT) for noninvasive treatment of non-melanoma skin cancers and keloids, proudly announces a new physician-user to its roster of leading Dermatologists and Radiation Oncologists. World- renowned expert in skin cancer, general and cosmetic dermatology, Jeffrey Klein, MD, of Orange County, Calif., now offers the SRT-100™ procedure, a nonsurgical treatment option for basal and squamous cell carcinoma that has more than a 95% cure rate.
A Mohs micrographic surgeon, Dr. Klein turned to the SRT-100™ for his patients who are not candidates for surgery and prefer a pain-free, scar-free and no downtime approach to treat non-melanoma skin cancers. He finds that the SRT-100™ is particularly ideal for the elderly who may be on medication or are simply weary of more surgery. The SRT-100™ is also well suited to active adults who wish to avoid messy bandaging, reconstruction and recovery time. According to skin cancer specialists, superficial radiotherapy is an affordable and cosmetically elegant option for treating sensitive or delicate areas and curvatures, like the eyes, nose, scalp and legs and can treat lesions up to 10cm in size.
“The SRT-100™ unit is a low energy curative radiation therapy that delivers precise and accurate x-rays to basal and squamous cell carcinomas without needles, layer by layer tissue removal or post-reconstructive surgery,” said Dr. Klein, a clinical professor of Dermatology at the University of California, Irvine. “It irradiates superficial tumors by focusing on the surface layers of skin while sparing underlying or surrounding healthy tissue for extremely high cure rates and excellent cosmetic results. A win-win, SRT treatment is cost conscious for my patients and the healthcare system overall,” added Dr. Klein.
Basal cell carcinoma (BCC) is the most common type of skin cancer and appears frequently on the head, neck and hands as a small, fleshy or bumpy nodule or red patch. Basal cell carcinomas can take many months or years to grow. Untreated, the cancer often will begin to bleed, crust over, heal and repeat the cycle. It can extend below the skin to the bone and nerves, causing considerable local damage. When found early and treated properly, the cure rate for both basal cell and squamous cell carcinomas is over 95 percent.
Unlike internal radiation therapy and its associated side effects that date back to the mid-20th century, the “Future is Now” as characterized by superficial radiation therapy. The SRT-100™ device leverages a proven form of radiation that has been advanced forward with state-of-the-art technology, providing dermatologists, radiation oncologists and their patients a cost-effective and highly developed clinical solution to non-melanoma skin cancers.
A retrospective assessment of over 1,700 patients who were treated for basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) using SRT-100™ showed a 98 percent cure rate over two years, and over 95 percent cure rate over five years. Published in the peer-reviewed Journal of the American Academy of Dermatology (JAAD), these remarkable cure rates are comparable with those obtained using current clinical standards.
About Dr. Jeffrey Klein
Dr. Jeffrey Klein is a dermatologic surgeon practicing in San Juan Capistrano and Newport Beach in Orange County, California. His practice encapsulates all of the general dermatology and cosmetic dermatology services needed for skin health and a healthy appearance. Dr. Klein is listed a Diplomat for the American Board of Dermatology, the American Board of Internal Medicine, and an affiliate of the American Board of Cosmetic Surgery. Dr. Klein is a pioneer and the inventor of Tumescent Liposuction who has trained more than 800 surgeons worldwide on this revolutionary technique.
About Sensus Healthcare
Sensus Healthcare LLC (Boca Raton, FL) is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit http://www.sensushealthcare.com
For Sensus Healthcare